JP2024545253A - 効率的なワクチン - Google Patents

効率的なワクチン Download PDF

Info

Publication number
JP2024545253A
JP2024545253A JP2024536100A JP2024536100A JP2024545253A JP 2024545253 A JP2024545253 A JP 2024545253A JP 2024536100 A JP2024536100 A JP 2024536100A JP 2024536100 A JP2024536100 A JP 2024536100A JP 2024545253 A JP2024545253 A JP 2024545253A
Authority
JP
Japan
Prior art keywords
polynucleotide
protein
virus
cell epitope
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545253A5 (https=
Inventor
渉 赤畑
エフ スミス，ジョナサン
レオ アレクサンダー，ジェファリー
隆 関田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlp Therapeutics Japan
Original Assignee
Vlp Therapeutics Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlp Therapeutics Japan filed Critical Vlp Therapeutics Japan
Publication of JP2024545253A publication Critical patent/JP2024545253A/ja
Publication of JP2024545253A5 publication Critical patent/JP2024545253A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024536100A 2021-12-17 2022-12-16 効率的なワクチン Pending JP2024545253A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163265634P 2021-12-17 2021-12-17
US63/265,634 2021-12-17
US202263393400P 2022-07-29 2022-07-29
US63/393,400 2022-07-29
PCT/JP2022/046430 WO2023113016A1 (en) 2021-12-17 2022-12-16 Efficient vaccine

Publications (2)

Publication Number Publication Date
JP2024545253A true JP2024545253A (ja) 2024-12-05
JP2024545253A5 JP2024545253A5 (https=) 2025-04-18

Family

ID=86774453

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536100A Pending JP2024545253A (ja) 2021-12-17 2022-12-16 効率的なワクチン

Country Status (5)

Country Link
US (1) US20230201333A1 (https=)
EP (1) EP4448770A4 (https=)
JP (1) JP2024545253A (https=)
TW (1) TW202338090A (https=)
WO (1) WO2023113016A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025121971A1 (ko) * 2023-12-07 2025-06-12 기초과학연구원 자가 증폭 rna를 포함하는 바이러스 유사 입자 제조를 위한 알파 바이러스 기반 벡터 시스템
WO2025263616A1 (en) * 2024-06-21 2025-12-26 Vlp Therapeutics Japan, Inc. Efficient vaccine

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510647A (ja) * 1998-04-08 2002-04-09 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 癌の治療のための方法および修飾細胞
WO2002072027A2 (en) * 2001-03-14 2002-09-19 University Of Alabama Research Foundation Oncolytic rna replicons
JP2008500399A (ja) * 2004-05-21 2008-01-10 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
WO2011005799A2 (en) * 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
CN111961138A (zh) * 2020-10-20 2020-11-20 苏州茂行生物科技有限公司 疫苗融合蛋白
US20200407402A1 (en) * 2020-06-29 2020-12-31 The Scripps Research Institute Stabilized Coronavirus Spike (S) Protein Immunogens and Related Vaccines
JP2021507713A (ja) * 2017-12-20 2021-02-25 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ アルファウイルスレプリコン粒子
WO2021160346A1 (en) * 2020-02-13 2021-08-19 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
US20210322541A1 (en) * 2020-04-17 2021-10-21 Vlp Therapeutics, Inc. Coronavirus vaccine
WO2021255270A1 (en) * 2020-06-19 2021-12-23 Ziphius Vaccines Self-amplifying sars-cov-2 rna vaccine

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510647A (ja) * 1998-04-08 2002-04-09 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 癌の治療のための方法および修飾細胞
WO2002072027A2 (en) * 2001-03-14 2002-09-19 University Of Alabama Research Foundation Oncolytic rna replicons
JP2008500399A (ja) * 2004-05-21 2008-01-10 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
WO2011005799A2 (en) * 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
JP2021507713A (ja) * 2017-12-20 2021-02-25 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ アルファウイルスレプリコン粒子
WO2021160346A1 (en) * 2020-02-13 2021-08-19 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
US20210322541A1 (en) * 2020-04-17 2021-10-21 Vlp Therapeutics, Inc. Coronavirus vaccine
WO2021255270A1 (en) * 2020-06-19 2021-12-23 Ziphius Vaccines Self-amplifying sars-cov-2 rna vaccine
US20200407402A1 (en) * 2020-06-29 2020-12-31 The Scripps Research Institute Stabilized Coronavirus Spike (S) Protein Immunogens and Related Vaccines
CN111961138A (zh) * 2020-10-20 2020-11-20 苏州茂行生物科技有限公司 疫苗融合蛋白

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATALIN KARIKO, ET AL.: "Suppression of RNA Recognition by Toll-like Receptors:The Impact of Nucleoside Modification and the", IMMUNITY, vol. Vol.23 (2), JPN6025039820, 2005, pages 165 - 175, ISSN: 0005698405 *
MICHAEL S D KORMANN, ET AL.: "Expression of therapeutic proteins afterdelivery of chemically modified mRNA in mice", NATURE BIOTECHNOLOGY, vol. 29, JPN6025039819, 9 January 2011 (2011-01-09), pages 154 - 159, ISSN: 0005698404 *

Also Published As

Publication number Publication date
US20230201333A1 (en) 2023-06-29
WO2023113016A1 (en) 2023-06-22
EP4448770A1 (en) 2024-10-23
TW202338090A (zh) 2023-10-01
EP4448770A4 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
JP7644993B2 (ja) コロナウイルスワクチン
WO2023234300A1 (en) Modified vaccine design developments
JP7788787B2 (ja) 遺伝子発現増強のための組成物および方法
US20180000912A1 (en) Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity
JP2023520354A (ja) コロナウイルスワクチン
US20240401081A1 (en) Cytokine immunotherapy
JP2024545253A (ja) 効率的なワクチン
US20240335528A1 (en) Efficient vaccine
WO2025263616A1 (en) Efficient vaccine
US20220062439A1 (en) Localized administration of rna molecules for therapy
CN118922546A (zh) 有效疫苗
BR112022021828B1 (pt) Vetor replicon de alfavírus imunologicamente ativo, composição e vacina

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260317